| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
8.08(B) |
| Last
Volume: |
2,144,916 |
Avg
Vol: |
1,949,015 |
| 52
Week Range: |
$44.82 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
6,762 |
108,398 |
166,494 |
290,334 |
| Total Sell Value |
$463,948 |
$6,570,910 |
$11,277,891 |
$18,676,003 |
| Total People Sold |
8 |
10 |
11 |
11 |
| Total Sell Transactions |
11 |
52 |
61 |
100 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Conroy Kevin T |
President and CEO |
• • – |
2022-02-14 |
4 |
OE |
$9.07 |
$4,342,004 |
D/D |
222,316 |
893,103 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2022-02-14 |
4 |
OE |
$78.33 |
$311,127 |
D/D |
3,972 |
8,150 |
|
- |
|
| Orville Jacob A |
General Manager, New Ventures |
• – – |
2022-02-14 |
4 |
OE |
$78.33 |
$159,010 |
D/D |
2,030 |
7,475 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,972 |
4,178 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
6,407 |
670,787 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2021-11-01 |
4 |
AS |
$93.88 |
$1,588,637 |
D/D |
(16,922) |
664,380 |
|
-41% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2021-10-01 |
4 |
AS |
$93.64 |
$1,599,184 |
D/D |
(17,078) |
681,302 |
|
-16% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2021-09-01 |
4 |
AS |
$104.42 |
$1,981,683 |
D/D |
(18,978) |
698,380 |
|
-28% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2021-08-02 |
4 |
AS |
$107.50 |
$2,146,775 |
D/D |
(19,970) |
717,358 |
|
-25% |
|
| Doyle James Edward |
Director |
– • – |
2021-07-30 |
4/A |
AS |
$111.17 |
$293,489 |
D/D |
(2,640) |
29,830 |
|
- |
|
| Napier Katherine S |
Director |
– • – |
2021-07-30 |
4/A |
AS |
$111.11 |
$153,439 |
D/D |
(1,381) |
34,741 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2021-07-30 |
4 |
S |
$111.17 |
$293,489 |
D/D |
(2,640) |
29,830 |
|
20% |
|
| Napier Katherine S |
Director |
– • – |
2021-07-30 |
4 |
S |
$111.11 |
$153,439 |
D/D |
(1,381) |
34,741 |
|
20% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2021-07-29 |
4/A |
AS |
$107.54 |
$4,273,530 |
D/D |
(38,361) |
206 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2021-07-29 |
4 |
S |
$107.54 |
$4,273,530 |
D/D |
(38,361) |
206 |
|
26% |
|
| Conroy Kevin T |
President and CEO |
• • – |
2021-07-01 |
4 |
AS |
$123.43 |
$960,779 |
D/D |
(7,784) |
737,328 |
|
-21% |
|
| Napier Katherine S |
Director |
– • – |
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
36,122 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
32,470 |
|
- |
|
| Petrovic Shacey |
Director |
– • – |
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
8,357 |
|
- |
|
| Clancy Paul J |
Director |
– • – |
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,567 |
5,496 |
|
- |
|
| Jacquet Pierre |
Director |
– • – |
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,599 |
11,753 |
|
- |
|
| Lewis-Hall Freda C |
Director |
– • – |
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,011 |
10,483 |
|
- |
|
| Levangie Daniel J |
Director |
– • – |
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,675 |
17,691 |
|
- |
|
| Sebelius Kathleen |
Director |
– • – |
2021-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,699 |
13,877 |
|
- |
|
| Condella Sarah |
SVP, Human Resources |
• – – |
2021-06-14 |
4/A |
AS |
$121.88 |
$667,455 |
D/D |
(5,450) |
80,482 |
|
- |
|
957 Records found
|
|
Page 11 of 39 |
|
|
0.20 (0.44%) 
